Dual Diagnosis of Aortic Stenosis and Cardiac Amyloidosis Linked to Higher Mortality Risk, Study Shows
核心洞察
A large cohort study reveals patients with both aortic stenosis (搜索) and transthyretin cardiac amyloidosis (搜索) face a 30% higher mortality risk compared to those with aortic stenosis alone.
The dual diagnosis group showed significantly elevated heart failure (搜索) hospitalization rates of 48.7%, compared to 29.4% in AS-only and 22.8% in ATTR-CA-only patients.
Researchers identify key clinical features for screening, including heart failure (搜索), cardiac arrhythmias, and carpal tunnel syndrome, potentially enabling earlier detection and treatment.
A nationwide study of over 355,000 patients has revealed significantly worse outcomes for individuals diagnosed with both aortic stenosis (搜索) (AS) and transthyretin cardiac amyloidosis (搜索) (ATTR-CA), highlighting the urgent need for improved screening and early intervention strategies.
The research, led by Dr. Ahmad Masri of Oregon Health & Science University, found that patients with both conditions faced a 30% higher mortality risk (HR 1.3, 95% CI 1.1-1.4) compared to those with AS alone. The two-year mortality rates were particularly telling: 19.2% for the dual diagnosis group, compared to 16.1% for AS-only and 14.8% for ATTR-CA-only patients.
Elevated Heart Failure Risk
Perhaps most striking was the nearly doubled risk of heart failure (搜索) hospitalization (HR 1.9, 95% CI 1.8-2.1) in patients with both conditions. The dual diagnosis group experienced a 48.7% hospitalization rate, significantly higher than the 29.4% rate in AS-only patients and 22.8% in those with ATTR-CA alone.
Diagnostic Challenges and Screening Opportunities
The study identified several key clinical features associated with the dual diagnosis, including:
- Heart failure
- Cardiac arrhythmias
- Cardiomegaly
- Carpal tunnel syndrome
- Chronic kidney disease
- Autonomic and peripheral neuropathy
These characteristics could serve as important screening indicators, potentially enabling the development of electronic medical record-based risk scores for ATTR-CA detection.
Treatment Landscape
The findings come at a crucial time when new treatment options are emerging. The FDA recently approved acoramidis (Attruby) for treating wild-type or variant ATTR-CM, adding to existing options like tafamidis (Vyndaqel or Vyndamax). However, researchers emphasize that early diagnosis remains critical, as these treatments are most effective when initiated early in the disease course.
Study Demographics and Limitations
The study population analysis revealed that the dual diagnosis group tended to be older (average 78.6 years) and predominantly male (59.1%). While only 0.3% of the total cohort had both conditions, this represents the largest published dataset of patients with dual diagnosis to date.
The research team acknowledges several limitations, including the lack of detailed echocardiographic data and potential selection biases in the cohort. Nevertheless, the findings strongly suggest the need for increased vigilance in screening and diagnosis, particularly given the availability of disease-modifying therapies.
Clinical Implications
Dr. Brett Sperry, in an accompanying editorial, emphasized the responsibility of healthcare providers to correctly diagnose and treat both conditions. The study's findings suggest that implementing systematic screening strategies, particularly among AS patients, could lead to earlier detection of ATTR-CA and potentially better outcomes through timely intervention.